)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shandong Weigao Group Medical Polymer Company
Shandong Weigao Group Medical Polymer Company (1066) investor relations material
Shandong Weigao Group Medical Polymer Company H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary25 Aug, 2026
Executive summary
Revenue for H1 2026 rose 3.1% year-over-year to RMB6,849m, with overseas revenue up 6.2% and contributing 25.2% of total sales.
Net profit attributable to owners dropped 23.2% to RMB774m, mainly due to margin pressure, non-recurring items, and foreign exchange losses; excluding extraordinary items, net profit was RMB890m, down 11.7% YoY but up 45.3% HoH.
Gross profit margin declined to 46.3% from 49.7% last year, primarily due to policy-driven price reductions in core product lines.
R&D expenses accounted for 4.4% of revenue, with 129 new product registrations in China, 150 new patents, and 59 new overseas product certificates in orthopaedics.
Strategic M&A activities advanced, including the Weigao Blood Purification transaction approved by the Shanghai Stock Exchange, pending CSRC registration.
Financial highlights
Total revenue: RMB6,849m in H1 2026, up from RMB6,644m in H1 2025.
Gross profit was RMB3,170.66m, down 4.0% YoY; net exchange loss increased to RMB91.38m from RMB41.34m last year.
Net cash inflow from operating activities was RMB1,077.69m; cash and bank balances stood at RMB7,719.70m as of June 30, 2026.
Gearing ratio improved to 16.7% from 21.2% at year-end 2025.
Dividend payout ratio maintained at 50% for H1 2026, with interim dividend of RMB0.0854 per share proposed, pending shareholder approval.
Outlook and guidance
Domestic healthcare demand is recovering slowly, with persistent price pressure and cautious procurement.
Overseas revenue growth outpaced domestic, but compliance and operational costs rose due to global volatility and exchange losses.
Focus on increasing new product share, optimizing product mix, and maintaining stable gross margin.
Continued expense management and commercial profit margin improvement targeted.
M&A integration and overseas expansion, including trial production in Indonesia and market entry in Côte d'Ivoire, are key priorities.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shandong Weigao Group Medical Polymer Company
- Record free cash flow and volume growth offset by procurement pressure and weaker profits.1066
H2 2023 - Strong profit and revenue growth, margin expansion, and strategic focus on high-value consumables.1066Q3 2009
- Revenue up 2.3% YoY, but profit fell nearly 20% as price and FX pressures hit margins.1066H2 2025
- Flat revenue, lower profit, margin pressure, and interim dividend proposed.1066H1 2025
- Revenue and profit fell, but pharma packaging and overseas sales grew; higher interim dividend proposed.1066H1 2024
- Adjusted net profit rose 4.2% to RMB2.07bn as overseas sales and dividends increased.1066H2 2024
Next Shandong Weigao Group Medical Polymer Company earnings date
H2 202626 Mar, 2027
Shandong Weigao Group Medical Polymer Company
Next Shandong Weigao Group Medical Polymer Company earnings date
H2 202626 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Shandong Weigao Group Medical Polymer Company Limited is a China-based manufacturer and supplier of medical devices and consumables. The company offers a wide range of products, including disposable medical consumables, orthopedic materials, and blood purification systems. Its products are used in various medical fields, such as infusion therapy, blood management, and surgical procedures. The company is headquartered in Weihai, China, and its shares are listed on the Hong Kong Stock Exchange.